| Literature DB >> 28610615 |
Rayabarapu Pranavchand1, Battini Mohan Reddy2.
Abstract
BACKGROUND: Given the characteristic atherogenic dyslipidemia of south Indian population and crucial role of APOA1, APOC3, APOA4 and APOA5 genes clustered in 11q23.3 chromosomal region in regulating lipoprotein metabolism and cholesterol homeostasis, a large number of recently identified variants are to be explored for their role in regulating the serum lipid parameters among south Indians.Entities:
Keywords: Dyslipidemia; Genetic association; Haplotype; Lipoprotein metabolism; Quantitative lipid traits
Mesh:
Substances:
Year: 2017 PMID: 28610615 PMCID: PMC5470178 DOI: 10.1186/s12944-017-0507-5
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Significant allelic associations of SNPs at 11q23.3 chromosomal region with the quantitative lipid traits obtained through linear regression analysisa
| SNP | Total cholesterol | LDL cholesterol | Triglycerides | VLDL | ||||
|---|---|---|---|---|---|---|---|---|
| β (95% CI) |
| β (95% CI) |
| β (95% CI) |
| β (95% CI) |
| |
| rs11216126 | −0.08 (−0.18 - -0.002) | 0.056* | ||||||
| rs11216129 | −0.08 (−0.18 - -0.002) | 0.055* | ||||||
| rs17440396 | 0.10 (0.01–0.19) | 0.022 | ||||||
| rs10488699 | 0.09 (0.002–0.18) | 0.044 | ||||||
| rs17119975 | −0.09 (−0.18 - -0.003) | 0.043 | −0.09 (−0.18 - -0.003) | 0.043 | ||||
|
|
|
|
|
| ||||
| rs1942478 | −0.11 (−0.20 - -0.02) | 0.017 | −0.11 (−0.20 - -0.19) | 0.017 | ||||
| rs4417316 | −0.10 (−0.19 - -0.01) | 0.025 | −0.10 (−0.19 - -0.01) | 0.029 | ||||
| rs6589566 | −0.10 (−0.23 - -0.05) | 0.0018 | −0.15 (−0.25 - -0.06) | 0.0007 | ||||
|
|
|
|
|
| ||||
| rs633867 | 0.09 (0.002–0.18) | 0.044 | ||||||
| rs672143 | −0.01 (−0.18 - -0.008) | 0.033 | −0.09 (−0.18 - -0.003) | 0.042 | ||||
| rs6589567 | 0.08 (−0.005–0.17) | 0.067* | 0.08 (−0.005–0.17) | 0.067* | ||||
|
|
|
|
|
| ||||
| rs2849165 | 0.09 (0.002–0.1 8) | 0.045 | ||||||
| rs2854117 | 0.10 (0.01–0.19) | 0.024 | 0.10 (0.01–0.19) | 0.026 | ||||
| rs2854116 | −0.10 (−0.20–0.003) | 0.044 | −0.11 (−0.21 - -0.01) | 0.021 | −0.11 (−0.21 - -0.01) | 0.024 | ||
| rs5132 | 0.09 (−0.0001–0.018) | 0.051* | 0.10 (0.01–0.19) | 0.027 | ||||
| rs11216153 | −0.009 (−0.18 - -0.005) | 0.038 | ||||||
| rs5081 | 0.13 (0.04–0.22) | 0.003 | 0.13 (0.04–0.22) | 0.0034 | 0.09 (0.003–0.18) | 0.042 | 0.09 (0.002–0.18) | 0.043 |
| rs5072 | 0.09 (0.0002–0.18) | 0.049 | ||||||
| rs632153 | 0.13 (0.03–0.22) | 0.006 | 0.11 (0.02–0.20) | 0.0139 | 0.11 (0.02–0.20) | 0.014 | 0.11 (0.02–0.20) | 0.015 |
β-Standardized linear regression coefficient, Blank cell – Non significant, bold font indicates significant after Benjamin Hochberg correction
*Significant after adjusting for covariates
aResults for lone SNP (rs918144(C) that belong to BUD13 gene) associated with HDLC are not given in the table but described with text
Significant haplotypes at 11q23.3 chromosomal region associated with LDL Cholesterol and Total cholesterol obtained through linear regression analysis
| SNPs in Haplotype block | Haplotype | Frequency | LDL Cholesterol | Total cholesterol | ||
|---|---|---|---|---|---|---|
| β (95% CI) |
| β (95% CI) |
| |||
| rs623908, rs664059 | AC | 0.21 | −6.06 (−11.1, −1.0) | 0.018 | ||
| rs6589566, rs2075290 | GC | 0.20 | −5.22 (−10.4, −0.1) | 0.047* | ||
| GT | 0.05 | −18.4 (−28.2, −8.6) | 0.0002 | −28.3 (−39.3, −17.3) | 7.39 × 10−07 | |
| AT | 0.74 | 7.97 (3.5, 12.4) | 0.0005 | 8.44 (3.3, 13.5) | 0.0012 | |
| rs633389, rs633867 | TT | 0.05 | 9.68 (0.5, 18.8) | 0.038 | ||
| TC | 0.10 | 16.5 (9.1, 23.9) | 1.47 × 10−05 | 16.4 (7.9, 24.9) | 0.0001 | |
| CC | 0.84 | −13.1 (−18.7, −7.5) | 5.25 × 10−06 | −12.6 (−19.0, −6.2) | 0.0001 | |
| rs5132, rs5128, rs11216153 | TGG | 0.039 | 17.7 (6.2, 29.2) | 0.0027 | 19.1 (5.9, 32.3) | 0.0047 |
* Not significant after adjusting for covariates age, sex and BMI
The haplotypes that are significantly associated with Triglycerides and VLDL
| SNPs in Haplotype block | Haplotype | Frequency | Triglycerides | VLDL | ||
|---|---|---|---|---|---|---|
| β (95% CI) |
| β (95% CI) |
| |||
| rs1942478, rs4417316 | GT | 0.34 | −14.9 (−29.0, −0.8) | 0.039 | −2.99 (−5.8, −0.2) | 0.038 |
| TC | 0.64 | 16.8 (2.9, 30.7) | 0.018 | 3.31 (0.5, 6.1) | 0.02 | |
| rs6589566, rs2075290 | GT | 0.05 | −45.3 (−78.2, −12.4) | 0.007 | −9.2 (−15.8, −2.6) | 0.006 |
| rs1160038, rs6589567 | CC | 0.30 | −14.5 (−28.9, −0.1) | 0.048 | −2.83 (−5.69, 0.03) | 0.053$ |
| rs5132, rs5128, rs11216153 | CCG | 0.36 | 14.6 (0.5, 28.7) | 0.043 | 2.92 (0.1, 5.7) | 0.043 |
$Significant only after adjusting for covariates age, sex and BMI
Significant allelic association of SNPs at 11q23.3 chromosomal region with dyslipidemia: Odds ratios from logistic regression of dyslipidemia on variant alleles, before and after adjusting for age, sex and BMI
| SNP ID | Gene/Functional relevance | Alleles | Minor Allele Frequency | Unadjusted | Adjusted for Age, Sex and BMI | |||
|---|---|---|---|---|---|---|---|---|
| Cases | Controls | OR |
| OR |
| |||
| rs17440396 |
|
| 0.24 | 0.18 | 1.4(1.04–1.98) | 0.025 | 1.5(1.08–2.18) | 0.015 |
| rs10488699 |
| 0.23 | 0.17 | 1.4(1.03–1.98) | 0.031 | 1.5(1.04–2.03) | 0.029 | |
| rs2187126a |
| 0.19 | 0.09 | 2.2(1.50–3.25) | 4.07 × 10−5 | 2.3(1.52–3.41) | 6.04 × 10−5 | |
| rs6589566 |
| G/A | 0.20 | 0.29 | 0.6(0.46–0.86) | 0.003 | 0.7(0.5–0.91) | 0.009 |
| rs633389a |
|
| 0.22 | 0.12 | 2.1(1.47–3.02) | 3.72 × 10−5 | 2.0(1.41–2.87) | 0.0001 |
| rs672143 | G/A | 0.00 | 0.03 | 0.1(0.01–0.63) | 0.002 | 0.1(0.01–0.72) | 0.022 | |
| rs1263163a |
| 0.30 | 0.14 | 2.6(1.86–3.57) | 7.16 × 10−9 | 3.1(2.15–4.52) | 2.19 × 10−9 | |
| rs1263171 |
| 0.48 | 0.40 | 1.4(1.07–1.82) | 0.013 | 1.3(1.03–1.72) | 0.024 | |
| rs2854116 |
| A/G | 0.40 | 0.48 | 0.7(0.54–0.97) | 0.032 | 0.7(0.56–0.98) | 0.038 |
| rs632153 |
|
| 0.04 | 0.02 | 2.2(1.04–4.84) | 0.035 | 2.4(1.08–5.22) | 0.030 |
Bold indicates risk increasing nature of the minor allele
aSignificant after correction for multiple testing
Fig. 1Effects of variants at 11q23.3 chromosomal region against dyslipidemia with relative to each of the quantitative lipid traits
Fig. 2Receiver Operating Curve indicating the area under curve (AUC) and the discriminative power of risk scores towards dyslipidemia